Addex Regains Rights to Parkinson's Drug Candidates from Merck
"We continue to strongly believe that mGluR4 is a highly attractive target for treating Parkinson's and other serious diseases," said Bharatt Chowrira, CEO of Addex. "We recognize the substantial challenges for the pharmaceutical industry today and we thank our partner for this collaboration and the significant advances we made together in targeting this important receptor. We remain committed to pursuing mGluR4 PAM for Parkinson's and other diseases."
Under the agreement, Addex will regain rights to intellectual property and know-how and can pursue the program independently.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.